ライフサイエンスコーパス: WBC count

1 2.49, p = 0.0001 for the highest quintile of WBC count).

2 C count and of the mean of baseline + year 3 WBC count.

3 or high risk (HR) on the basis of diagnostic WBC count.

4 symptoms were not associated with hs-CRP or WBC count.

5 esponses occurred in AML with low presenting WBC count.

6 ctively) and were not associated with age or WBC count.

7 -165C>T)] was associated with an increase in WBC counts.

8 Higher expression was associated with higher WBC counts.

9 association between the MD and both PLT and WBC counts.

10 pronounced in those with progressively lower WBC counts.

11 netic classifier, MRD, and white blood cell (WBC) count.

12 , platelet count (PLT) and white blood cell (WBC) count.

13 in patients with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 4.9% for WBC count 5 to 10x10(

14 o associated with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 5.2% for WBC count 5 to 10x10(

15 rates were higher in patients with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 4.9% for WBC

16 e or shock was also associated with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 5.2% for WBC

17 4.9% for WBC count 5 to 10x10(9)/L, 3.8% for WBC count 10 to 15x10(9)/L, 10.4% for WBC count >15x10(9

18 5.2% for WBC count 5 to 10x10(9)/L, 6.1% for WBC count 10 to 15x10(9)/L, 17.1% for WBC count >15x10(9

19 parent thrombus was associated with a higher WBC count (11.5+/-5.2x10(9)/L, n=290, versus 10.7+/-3.5x

20 .04), a lower nadir in the white blood cell (WBC) count (2,818 versus 3,558 cells/microliter; P = 0.0

21 dian age, 54 years; median white blood cell [WBC] count 4,500/microL).

22 t (0% for WBC count 0 to 5x10(9)/L, 4.9% for WBC count 5 to 10x10(9)/L, 3.8% for WBC count 10 to 15x1

23 t (0% for WBC count 0 to 5x10(9)/L, 5.2% for WBC count 5 to 10x10(9)/L, 6.1% for WBC count 10 to 15x1

24 a higher median diagnostic white blood cell (WBC) count (71.5 vs 19.6 x 10(9)/L; P =.005) and lower c

25 the variation in baseline white blood cell (WBC) count, a characteristic that correlates with mortal

26 ificant calcium, phosphorus, electrolyte, or WBC count abnormalities were encountered.

27 statistically significant decrease in total WBC counts among exposed workers [IL-1A (-889C>T), IL-4

28 effect of birth weight on white blood cell (WBC) count among blacks and whites was examined in 2,080

29 There was poor correlation between the WBC count and absolute neutrophil counts (ANCs) and both

30 The WBC count and all-cause, cardiovascular, and cancer mort

31 We examined the relationship between the WBC count and angiographic findings to gain insight into

32 ers, assessment of two inflammatory markers, WBC count and CRP, can be used to stratify patients acro

33 tors, there was a direct association between WBC count and incidence of coronary heart disease (p < 0

34 The association between WBC count and MDS disappeared when further adjusted for

35 same gene or group of genes influences both WBC count and mean platelet volume (MPV).

36 ell (WBC) count and the relationship between WBC count and mortality between 1958 and 2002.

37 hazards associated with deciles of baseline WBC count and of the mean of baseline + year 3 WBC count

38 tudy evaluated the relation between baseline WBC count and other risk factors, as well as subclinical

39 fied the inverse association between MDS and WBC count and partially accounted for the association wi

40 Comparisons of mean WBC count and platelet nadirs for L-PAM alone and L-PAM

41 However, the relationship between WBC count and prognosis following AMI is less clear.

42 ence is increasing for a correlation between WBC count and thrombosis, but prospective data are lacki

43 m3), total protein (>2.5 g/dL), and combined WBC count and total protein (45.8%, 74.4%, and 81.3%, re

44 Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays

45 te observed among AMI patients with elevated WBC counts and helps explain the growing body of literat

46 effusions with relatively low pleural fluid WBC counts and LDH levels.

47 Red marrow dose, baseline platelet or WBC counts and multiple bone or marrow (or both) metasta

48 The correlations between WBC counts and risk factors were similar in both the ent

49 Similarly, there is a correlation between WBC counts and scintigraphy in most segments of the larg

50 genetic mechanisms that regulate circulating WBC counts and suggest a prominent shared genetic archit

51 ationship between baseline white blood cell (WBC) count and angiographic and clinical outcomes in pat

52 be an interaction between white blood cell (WBC) count and bivalirudin for the risk of mortality, an

53 L) were analyzed for total white blood cell (WBC) count and differential cell count, along with gelat

54 ed the association between white blood cell (WBC) count and incidence of coronary heart disease and i

55 redictive ability of total white blood cell (WBC) count and its subtypes for risk of death or myocard

56 had a significantly lower white blood cell (WBC) count and lactate dehydrogenase (LDH) level than di

57 atory responses [change in white blood cell (WBC) count and neutrophil activity], and that these resp

58 ul were the synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells fro

59 gated the secular trend in white blood cell (WBC) count and the relationship between WBC count and mo

60 ration, hematocrit levels, white blood cell (WBC) counts and platelet counts in 31,340 individuals ge

61 ivariable Cox regression analysis, sex, age, WBC count, and cytogenetic risk category were related to

62 sex, blood pressure, serum HDL cholesterol, WBC count, and history of current cigarette smoking; and

63 smoking, higher CRP, factor VII, fibrinogen, WBC count, and lower albumin and hemoglobin levels remai

64 range, 17 to 85 years), performance status, WBC count, and mutation status of NPM1, CEBPA, and FLT3-

65 hsCRP, WBC count, and serum albumin were measured at baseline i

66 ue Index (PI), Gingival Index (GI), systemic WBC counts, and peripheral neutrophil oxidative activity

67 en race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast c

68 otein (CRP) concentration, white blood cell (WBC) count, and absolute neutrophil cell (ANC) count for

69 h age at presentation, low white blood cell (WBC) count, and low fluorescence intensity of surface CD

70 ein (hsCRP) levels, higher white blood cell (WBC) counts, and lower serum albumin levels, are associa

71 White blood cell (WBC) count appears to predict total mortality and corona

72 Higher WBC counts are associated with higher mortality in succe

73 (99m)Tc-WBC scintigraphy, ESR, and WBC counts are good indicators of the inflammatory activ

74 Platelet (PLT) and white blood cell (WBC) counts are 2 markers of inflammation and have been

75 outcome or add to the value of an increased WBC count as a negative prognostic indicator in APL pati

76 include patients 1 to 9 years of age with a WBC count at diagnosis less than 50,000/microL.

77 P = .0001), independent of age (P = .25) and WBC count at presentation (P = .003).

78 FHIT methylation was associated with high WBC counts at diagnosis, a known prognostic indicator.

79 In the cases, white blood cells (WBC) count at diagnosis was compared to prediagnosis; an

80 ents with ALL in CR2 (1) for patients with a WBC count (at diagnosis) of 20 x 10(9)/L or higher (DFS,

81 hsCRP), lipid profile, and white blood cell (WBC) count, at baseline and 1, 3, and 6 months.

82 Filgrastim increased WBC counts (baseline median, 13.3x109/L; median peak, 43

83 ere were no differences in age or presenting WBC counts between the cases with or without positive ne

84 In multivariate analyses, peak WBC count, birth weight, intubation, and receipt of nitr

85 bles: red marrow dose, baseline platelet and WBC counts, bone or marrow (or both) metastases, prior c

86 low-frequency power by 90% (P = 0.01), total WBC count by 139% (P = 0.006), and lymphocyte count by 1

87 duals and hospitalized patients with similar WBC counts can be robustly classified based on their WBC

88 no differences in initial white blood cell (WBC) count, central nervous system disease, and risk gro

89 del of survival adjusted for age group, sex, WBC count, chloroma, CNS involvement, and French-America

90 WBC counts correlated (p < 0.01) positively with coagula

91 In contrast, WBC counts correlated negatively with high density lipop

92 operative Oncology Group performance status, WBC count, creatinine clearance, albumin, AST, number of

93 by prognostic factors in addition to age and WBC count criteria, and that a common set of prognostic

94 nts with T-cell ALL based on the uniform age/WBC count criteria.

95 d 8 other prognostic factors, including age, WBC count, cytogenetics, and gene mutations, into surviv

96 king status (in adolescents and adults), the WBC count decreased across quartiles of increasing birth

97 The median WBC count decreased from 36,900/microL before treatment

98 label-free smartphone based electrochemical WBC counting device on microporous paper with patterned

99 Elevated WBC count during follow-up was correlated with thrombosi

100 Elevation of the white blood cell (WBC) count during acute myocardial infarction (AMI) is a

101 onal inflammatory markers (white blood cell [WBC] count, erythrocyte sedimentation rate [ESR], C-reac

102 C-reactive protein (CRP), white blood cell (WBC) count, fibrinogen, factor VII, albumin, and hemoglo

103 c variation in circulating white blood cell (WBC) counts from large samples of otherwise healthy indi

104 se variants in CXCR2 associated with reduced WBC count (gene-based P = 2.6 x 10(-13)).

105 Age, initial WBC count, genetic aberrations, and minimal residual dis

106 Other outcomes included weekly WBC counts, graft incorporation, and quantitative cultur

107 ed ASXL1 mutations, age older than 65 years, WBC count greater than 15 x10(9)/L, platelet count less

108 0) and increased odds of being in the lowest WBC-count group (IMI: odds ratio = 1.41; 95% confidence

109 6) with high-risk ALL (aged 1 to 9 years and WBC count > or = 50,000/microL or age > or = 10 years, e

110 olute neutrophil count >/= 10,000/mm(3) or a WBC count >/= 10,000/mm(3) was reached, both counts serv

111 Patients harboring a WBC count >/=200 x 10(9)/L, gHiR classifier, and MRD >/=

112 When combined with MRD and a WBC count >/=200 x 10(9)/L, it identifies a significant

113 1% for WBC count 10 to 15x10(9)/L, 17.1% for WBC count >15x10(9)/L; P<0.001), an observation that rem

114 8% for WBC count 10 to 15x10(9)/L, 10.4% for WBC count >15x10(9)/L; P=0.03).

115 Patients with white blood cell (WBC) counts >50,000/microL began ATRA on day 1 and G-CSF

116 African Americans in the highest quartile of WBC count (> or =7,000 cells/mm(3)) had 1.9 times the ri

117 ed models (P < .01); the highest quartile of WBC counts (>/=6500 cells/microL) was associated with in

118 mon ascitic fluid tests of white blood cell (WBC) count (>500/mm3), total protein (>2.5 g/dL), and co

119 An elevated WBC count has been associated with cardiovascular risk,

120 A higher white blood cell (WBC) count has been shown to be a risk factor for myocar

121 Elevations in WBC count have been associated with the development of A

122 spital lengths of stay) and incremental peak WBC counts (hospital length of stay only).

123 sed systemic inflammation as depicted by the WBC count in childhood and adulthood, thereby potentiall

124 , birth weight was inversely associated with WBC count in children (beta coefficients (unit, cells/mi

125 re each independently associated with higher WBC counts in adjusted models (P < .01); the highest qua

126 The authors conclude that WBC counts in the elderly are associated with prevalent

127 At each site and in each year, WBC counts in the Plasmodium falciparum-infected patient

128 greatly reduced peripheral white blood cell (WBC) counts in leukemia recipient mice and induced apopt

129 d ratio (LR) increased as the synovial fluid WBC count increased (for counts <25,000/microL: LR, 0.32

130 The WBC count is a clinical marker of inflammation and a str

131 WBC count is also a complex trait that varies among indi

132 An increasing WBC count is associated with a significantly higher risk

133 Total WBC count is confirmed to be an independent predictor of

134 An elevated WBC count is directly associated with increased incidenc

135 White blood cell (WBC) count is a common clinical measure used as a predic

136 Elevated white blood cell (WBC) count is associated with increased major adverse ca

137 9 years of age at diagnosis with an initial WBC count less than 10,000/microL, were eligible for thi

138 26-treated mice achieved a white blood cell (WBC) count less than 20.0 x 10(9)/L (20,000/microL) at n

139 25 low- risk patients (WBC count < 10,000/microl) received ATRA (45 mg/m2 daily

140 anced by CYC-induced reductions in the total WBC count < 3,000 cells/microliter and by sequential IV

141 of 46%, whereas the 58 patients (30%) with a WBC count <200 x 10(9)/L, gLoR classifier, and MRD <10(-

142 io [HR] = 0.58, P = .002), white blood cell (WBC) count <10 x 10(9)/L (HR = 0.60, P = .005), and ETV6

143 30% bone marrow blasts and white blood cell (WBC) counts </=15 x 109/L (AZA-AML-001 study).

144 <30%) or first leukopenia (white blood cell [WBC] count <3000 cells/mm), which required clinical inte

145 their counterparts in the lowest quartile of WBC count (<4,800 cells/mm(3)).

146 genotype and the cellular milieu defined by WBC counts may influence HIV disease course, and this ma

147 with higher values for the white blood cell (WBC) count (median 2,500/microL v 1,600/microL; P = .009

148 Current WBC counting method relies on bulky instrument and train

149 (WT) or Tet2(+/-) BM cells, led to increased WBC counts, monocytosis, and splenomegaly in WT recipien

150 Patients with a WBC count more than 200,000/microL at diagnosis and an M

151 WBC count more than 50,000/microL was an adverse prognos

152 f chemotherapy, and B-precursor disease with WBC counts more than 100,000/microL all relapsed unless

153 EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequen

154 up by the investigators because of decreased WBC counts, mostly outside of study protocol criteria, d

155 gnostic factors such as cytogenetic risk and WBC count, neither the presence of EMD nor the number of

156 up displayed a significantly increased total WBC count, neutrophil count, and percent neutrophils com

157 Circulating white blood cell (WBC) counts (neutrophils, monocytes, lymphocytes, eosino

158 ered from MLD(-) patients only by lower mean WBC counts, not by biologic characteristics, cytogenetic

159 Fourteen patients (8.0%) had a WBC count of >50.0 x 10(9)/microL.

160 tients experienced leukopenia, with a median WBC count of 2,900 (range, 800 to 3,900) at nadir.

161 arasite densities on the basis of an assumed WBC count of 8000 cells/microL.

162 L or higher (DFS, 40% v 0%) and those with a WBC count of less than 20 x 10(9)/L (DFS, 73% v35%), (2)

163 gnostic factors were age less than 3 months, WBC count of more than 50,000/microL, CD10 negativity, s

164 h of the P. falciparum-infected patients had WBC counts of <4000 cells/microL.

165 ed idarubicin because of a white blood cell (WBC) count of more than 30 000/microL.

166 and had median presenting white blood cell (WBC) counts of 10 950/microL (range, 2900-70 300/microL)

167 ne the association between white blood cell (WBC) count on admission and 30-day mortality in patients

168 L, such as older age, high white blood cell (WBC) count, organomegaly, T-lineage immunophenotype, abi

169 evaluated the relationship between baseline WBC count, other baseline variables and biomarkers, angi

170 des evidence for a secular downward trend in WBC count over the period from 1958 to 2002.

171 Higher CRP (P < 0.001), WBC count (P < 0.001), fibrinogen (P < 0.001), and facto

172 2), hematocrit levels (P = 9.5 x 10(-7)) and WBC count (P = 3.1 x 10(-5)).

173 Children had significantly higher baseline WBC counts (P < .001).

174 n, including decreased CSF white blood cell (WBC) count (P < .001), interleukin (IL)-4 (P = .02), IL-

175 or the association of S-form type and higher WBC count; P = .40).

176 acteremia, altered liver function, increased WBC counts, pathogen-specific Ab (IgM and IgG), and cell

177 I, 8.26-10.49), and higher white blood cell (WBC) count (per 1000/muL: beta = 0.95; 95% CI, 0.74-1.16

178 ransplantation, diagnostic white blood cell (WBC) count, Ph chromosome status, and ploidy was 6.0% hi

179 A high WBC count, raised serum ALT, raised serum total bilirubi

180 or 10 days, until the peak white blood cell (WBC) count reached 75x109/L, until discharge from the ho

181 PBSC collections were initiated when the WBC count recovered to greater than 1 x 10(9)/L.

182 or patients with low, intermediate, and high WBC counts, respectively (p = 0.0017).

183 vival in a univariate analysis included age, WBC count, Sanz classification, and percent blood blasts

184 Age, WBC count, secondary AML, Eastern Cooperative Oncology G

185 Limited data exist on the WBC count secular trend and the relationship between WBC

186 ia chromosome status, age, white blood cell (WBC) count, sex, race, and ploidy group (P =.01).

187 sed artery at 60 and 90 minutes had higher a WBC count than patients with an open artery (P:=0.02).

188 chomatis infection had a 0.43 log(10) higher WBC count than their HIV-uninfected, chlamydia-positive

189 ry, on average, have lower white blood cell (WBC) counts than those of European descent (ethnic leuko

190 whereas animals injected with PYKK081 had a WBC count that resembled that of the uninfected control.

191 nd differential peripheral white blood cell (wbc) counts, together with full mouth plaque and gingivi

192 first apheresis performed when the recovery WBC count was > or = 5.0 x 10(9)/L.

193 The median nadir WBC count was 1.4 x 10(3)/microL.

194 Her WBC count was 10,370/muL, with a differential showing 5%

195 myocardial infarction (NSTEMI) and to see if WBC count was a significant predictor of outcomes indepe

196 on between bivalirudin therapy and admission WBC count was apparent for 1-year mortality.

197 In addition, a higher WBC count was associated with poorer TIMI myocardial per

198 Elevation in WBC count was associated with reduced epicardial blood f

199 patients enrolled in the HORIZONS-AMI trial, WBC count was available in 3433 (95.3%) patients.

200 After adjustment for confounding factors, WBC count was found to be a strong independent predictor

201 Collections were initiated when the WBC count was greater than 10 x 10(9)/L or 4 days after

202 WBC count was independently associated with somatic depr

203 WBC count was measured at baseline in 160,117 postmenopa

204 The WBC count was nonlinearly associated with all-cause mort

205 A downward trend in WBC count was observed from 1958 to 2002.

206 A higher baseline WBC count was predictive of higher six-month mortality,

207 The median white blood cell (WBC) count was 1,450/microL at diagnosis and was 31,000/

208 Average white blood cell (WBC) count was 37.7 x 10(9)/microL.

209 High deciles of both baseline and mean WBC count were positively associated with total mortalit

210 Lower albumin and %LYM and a higher WBC count were significantly associated with outcomes.

211 Higher baseline WBC counts were associated with lower Thrombolysis In My

212 PLT and WBC counts were both inversely related to MD adherence (

213 Higher WBC counts were significantly associated with positive b

214 perative level for 1 year posttransplant and WBC counts were significantly lower for 3 years after tr

215 WBC counts were statistically significantly higher in pe

216 and HIV disease markers or white blood cell (WBC) count were examined using mixed-effects and linear

217 n a simple, widely available blood test, the WBC count, were associated with impaired epicardial and

218 nce status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic fact

219 antly elevated circulating white blood cell (WBC) count, whereas animals injected with PYKK081 had a

220 The association of WBC count with mortality was independent of smoking and

221 th Initiative to examine the associations of WBC count with total mortality, CHD mortality, and cance

222 ith electrocardiogram, and white blood cell (WBC) counts with hematology analyzer.

223 to keep the platelet count, and arguably the WBC count, within the normal range.